Screening of an FDA‐approved compound library identifies levosimendan as a novel anti‐HIV‐1 agent that inhibits viral transcription

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Antiviral Research

• Publication date

  2017-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.antiviral.2017.08.013PMID 28842263PMCID PMC5654649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association

  2017cited by this paper
• HIV Latency: Should We Shock or Lock?

  2017cited by this paper
• Lessons learned from human HIV vaccine trials

  2017cited by this paper
• HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations

  2017cited by this paper
• Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells

  2016cited by this paper
• Calcium sensitizers: What have we learned over the last 25 years?

  2016cited by this paper
• An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

  2015cited by this paper
• IFI44 suppresses HIV-1 LTR promoter activity and facilitates its latency.

  2015cited by this paper
• FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency*

  2015cited by this paper
• Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

  2015cited by this paper
• Levosimendan inhibits interleukin-1β-induced apoptosis through activation of Akt and inhibition of inducible nitric oxide synthase in rat cardiac fibroblasts.

  2015cited by this paper
• Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

  2015cited by this paper
• Targeting HIV transcription: the quest for a functional cure.

  2015cited by this paper
• The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency

  2015cited by this paper
• Comprehensive Identification of Host Modulators of HIV-1 Replication using Multiple Orthologous RNAi Reagents

  2014cited by this paper
• Eradicating HIV-1 infection: seeking to clear a persistent pathogen

  2014cited by this paper
• Levosimendan: current data, clinical use and future development

  2013cited by this paper
• An integrated overview of HIV-1 latency.

  2013cited by this paper
• Kinase Control of Latent HIV-1 Infection: PIM-1 Kinase as a Major Contributor to HIV-1 Reactivation

  2013cited by this paper
• Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects

  2013cited by this paper
• Targeting HIV latency: pharmacologic strategies toward eradication.

  2013cited by this paper
• Reactivation of latent HIV-1 by inhibition of BRD4.

  2012cited by this paper
• Therapeutic vaccines against HIV infection

  2012cited by this paper
• Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

  2012cited by this paper
• Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

  2012cited by this paper
• An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.

  2012cited by this paper
• Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

  2011cited by this paper
• HIV latency.

  2011cited by this paper
• Levosimendan Modulates Programmed Forms of Cell Death Through KATP Channels and Nitric Oxide

  2011cited by this paper
• A dumbbell-shaped small molecule that promotes cell adhesion and growth.

  2009cited by this paper
• 9-aminoacridine Inhibition of HIV-1 Tat Dependent Transcription

  2009cited by this paper
• Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells.

  2009cited by this paper
• Effects of levo‐ and dextrosimendan on NF‐κB‐mediated transcription, iNOS expression and NO production in response to inflammatory stimuli

  2008cited by this paper
• The contribution of in vitro toxicity data in hazard and risk assessment: current limitations and future perspectives.

  2008cited by this paper
• A review of levosimendan in the treatment of heart failure

  2006cited by this paper
• Two Inotropes With Different Mechanisms of Action: Contractile, PDE-Inhibitory and Direct Myofibrillar Effects of Levosimendan and Enoximone

  2005cited by this paper
• The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.

  2004cited by this paper
• HIV reproducibly establishes a latent infection after acute infection of T cells in vitro

  2003cited by this paper
• Sustained Hemodynamic Effects of Intravenous Levosimendan

  2003cited by this paper
• Recruitment of Phosphatidylinositol 3-Kinase to CD28 Inhibits HIV Transcription by a Tat-Dependent Mechanism1

  2002cited by this paper
• A quantitative assay for HIV DNA integration in vivo

  2001cited by this paper
• Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo

  2000cited by this paper
• The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.

  1997cited by this paper
• Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.

  1995cited by this paper

• Current treatment of HIV and prospects for cure

  2025cites this paper
• Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques

  2024cites this paper
• Interventions during Early Infection: Opening a Window for an HIV Cure?

  2024cites this paper
• HIV-Tocky system to visualize proviral expression dynamics

  2023cites this paper
• Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR

  2023cites this paper
• Role of microglia in HIV-1 infection

  2023cites this paper
• Toward a Functional Cure for HIV-1 Infection: The Block and Lock Therapeutic Approach

  2022cites this paper
• Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation

  2022cites this paper
• HIV cure strategies: which ones are appropriate for Africa?

  2022cites this paper
• Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency.

  2021cites this paper
• Characterizing Transcriptional Dynamics of HIV-1 in T-cells and Macrophages Using a Three-State LTR Model

  2021cites this paper
• Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy

  2021cites this paper
• Shock-and-kill versus block-and-lock: Targeting the fluctuating and heterogeneous HIV-1 gene expression

  2021cites this paper
• HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES.

  2021cites this paper
• The Splice of Life: Does RNA Processing Have a Role in HIV-1 Persistence?

  2021cites this paper
• Moving Toward a Functional Cure for HIV-1

  2021cites this paper
• Exploring nature’s bounty: identification of Withania somnifera as a promising source of therapeutic agents against COVID-19 by virtual screening and in silico evaluation

  2020cites this paper
• Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

  2020cites this paper
• Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy

  2020cites this paper
• Therapeutic Development and Drugs for the Treatment of COVID-19

  2020cites this paper
• Novel Approaches Towards a Functional Cure of HIV/AIDS

  2020cites this paper
• Mathematical analysis and potential therapeutic implications of a novel HIV-1 model of basal and activated transcription in T-cells and macrophages

  2020cites this paper
• Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro)

  2020cites this paper
• Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.

  2020cites this paper
• Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2

  2020cites this paper
• Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection

  2020cites this paper
• Block-And-Lock: New Horizons for a Cure for HIV-1

  2020influential citation
• Overview of Recent Strategic Advances in Medicinal Chemistry.

  2019cites this paper
• Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors

  2019cites this paper
• Discovery of novel elongator protein 2 inhibitors by compound library screening using surface plasmon resonance

  2019cites this paper
• Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies

  2019cites this paper
• Pharmacological and Nutritional Effects of Natural Coumarins and Their Structure–Activity Relationships

  2018cites this paper
• The role of exosomal transport of viral agents in persistent HIV pathogenesis

  2018cites this paper
• Barriers for HIV Cure: The Latent Reservoir

  2018cites this paper
• Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation

  2017cites this paper